To investigate the anticoagulant effect of dabigatran etexilate in elderly patients with non-valvular atrial fibrillation by multi-omics technology

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300077836

Enrollment

Unknown

Registered

2023-11-21

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Normal coagulation function group:NA

Abnormal coagulation function group:NA

Eligibility

Sex/Gender

All

Age

60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Patients aged more than 60 years old and less than 90 years old; 2) patients with NVAF diagnosed by a cardiologist; 3) the patient was receiving anticoagulant therapy with dabigatran etexilate;

Exclusion criteria

Exclusion criteria: 1) combined with malignant diseases in the past or during treatment; 2) reversible factors such as perioperative seizures, hyperthyroidism and other endocrine factors; 3) women who are pregnant or lactating; 4) weight loss >10% in the past three months; 5) drug addiction, long-term alcohol abuse and HIV/AIDS patients; 6) patients with uncontrollable seizures or loss of self-control due to psychosis.

Design outcomes

Primary

Measure	Time frame
Dabigatran drug concentration;	—

Secondary

Measure	Time frame
diluted thrombin time;Quantitative Multiomics Analysis;	—

Countries

China

Contacts

Public ContactZHAO MINDI

Beijing hospital

mindizhao@163.com+86 10 8513 6013

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026